BACKGROUND: Older age has historically been an adverse prognostic factor in pediatric acute myeloid leukemia (AML). To the authors' knowledge, the impact of age relative to that of other prognostic factors on the outcome of patients treated in recent trials is unknown. METHODS: Clinical outcome and causes of treatment failure of 351 patients enrolled on 3 consecutive protocols for childhood AML between 1991 and 2008 were analyzed according to age and protocol. RESULTS: The more recent protocol (AML02) produced improved outcomes for patients aged 10 years to 21 years compared with 2 earlier studies (AML91 and AML97), with 3-year rates of event-free survival (EFS), overall survival (OS), and cumulative incidence of refractory leukemia or recurrence (CIR) for this group being similar to those of patients aged birth to 9 years: EFS: 58.3% ± 5.4% versus 66.6% ± 4.9% (P = .20); OS: 68.9% ± 5.1% versus 75.1% ± 4.5% (P = .36); and CIR: 21.9% ± 4.4% versus 25.3% ± 4.2% (P = .59). The EFS and OS estimates for patients aged 10 to 15 years overlapped those for patients aged 16 to 21 years. However, the cumulative incidence of toxic death was significantly higher for patients aged 10 to 21 years compared with younger patients (13.2% ± 3.6% vs 4.5% ± 2.0%; P = .028). CONCLUSIONS: The survival rate for older children with AML has improved on the results of a recent trial and is now similar to that of younger patients. However, deaths from toxicity remain a significant problem for patients in the older age group. Future trials should focus on improving supportive care while striving to develop more effective antileukemic therapy.
RCT Entities:
BACKGROUND: Older age has historically been an adverse prognostic factor in pediatric acute myeloid leukemia (AML). To the authors' knowledge, the impact of age relative to that of other prognostic factors on the outcome of patients treated in recent trials is unknown. METHODS: Clinical outcome and causes of treatment failure of 351 patients enrolled on 3 consecutive protocols for childhood AML between 1991 and 2008 were analyzed according to age and protocol. RESULTS: The more recent protocol (AML02) produced improved outcomes for patients aged 10 years to 21 years compared with 2 earlier studies (AML91 and AML97), with 3-year rates of event-free survival (EFS), overall survival (OS), and cumulative incidence of refractory leukemia or recurrence (CIR) for this group being similar to those of patients aged birth to 9 years: EFS: 58.3% ± 5.4% versus 66.6% ± 4.9% (P = .20); OS: 68.9% ± 5.1% versus 75.1% ± 4.5% (P = .36); and CIR: 21.9% ± 4.4% versus 25.3% ± 4.2% (P = .59). The EFS and OS estimates for patients aged 10 to 15 years overlapped those for patients aged 16 to 21 years. However, the cumulative incidence of toxic death was significantly higher for patients aged 10 to 21 years compared with younger patients (13.2% ± 3.6% vs 4.5% ± 2.0%; P = .028). CONCLUSIONS: The survival rate for older children with AML has improved on the results of a recent trial and is now similar to that of younger patients. However, deaths from toxicity remain a significant problem for patients in the older age group. Future trials should focus on improving supportive care while striving to develop more effective antileukemic therapy.
Authors: Bassem I Razzouk; Elihu Estey; Stanley Pounds; Shelly Lensing; Sherry Pierce; Mark Brandt; Jeffrey E Rubnitz; Raul C Ribeiro; Michael Rytting; Ching-Hon Pui; Hagop Kantarjian; Sima Jeha Journal: Cancer Date: 2006-06-01 Impact factor: 6.860
Authors: Thomas Lehrnbecher; Martin Zimmermann; Dirk Reinhardt; Michael Dworzak; Jan Stary; Ursula Creutzig Journal: Blood Date: 2006-09-28 Impact factor: 22.113
Authors: R A Krance; C A Hurwitz; D R Head; S C Raimondi; F G Behm; K R Crews; D K Srivastava; H Mahmoud; W M Roberts; X Tong; R L Blakley; R C Ribeiro Journal: J Clin Oncol Date: 2001-06-01 Impact factor: 44.544
Authors: Beth Kurt; Patricia Flynn; Jerry L Shenep; Stanley Pounds; Shelly Lensing; Raul C Ribeiro; Ching-Hon Pui; Bassem I Razzouk; Jeffrey E Rubnitz Journal: Cancer Date: 2008-07-15 Impact factor: 6.860
Authors: Ursula Creutzig; Thomas Büchner; Maria C Sauerland; Martin Zimmermann; Dirk Reinhardt; Hartmut Döhner; Richard F Schlenk Journal: Cancer Date: 2008-02-01 Impact factor: 6.860
Authors: Jeffrey E Rubnitz; Shelly Lensing; Yinmei Zhou; John T Sandlund; Bassem I Razzouk; Raul C Ribeiro; Ching-Hon Pui Journal: Cancer Date: 2004-10-01 Impact factor: 6.860
Authors: Ditte J A Løhmann; Jonas Abrahamsson; Shau-Yin Ha; Ólafur G Jónsson; Minna Koskenvuo; Birgitte Lausen; Josefine Palle; Bernward Zeller; Henrik Hasle Journal: Haematologica Date: 2016-07-28 Impact factor: 9.941
Authors: Ursula Creutzig; Matthew A Kutny; Ronald Barr; Richard F Schlenk; Raul C Ribeiro Journal: Pediatr Blood Cancer Date: 2018-04-18 Impact factor: 3.167
Authors: Seth E Karol; Elaine Coustan-Smith; Xueyuan Cao; Sheila A Shurtleff; Susana C Raimondi; John K Choi; Raul C Ribeiro; Gary V Dahl; William Paul Bowman; Jeffrey W Taub; Barbara Degar; Wing Leung; James R Downing; Ching-Hon Pui; Jeffrey E Rubnitz; Dario Campana; Hiroto Inaba Journal: Br J Haematol Date: 2014-08-28 Impact factor: 6.998
Authors: Maya Schulpen; Bianca F Goemans; Gertjan J L Kaspers; Marc H G P Raaijmakers; C Michel Zwaan; Henrike E Karim-Kos Journal: Int J Cancer Date: 2021-12-16 Impact factor: 7.316
Authors: David A Siegel; Lisa C Richardson; S Jane Henley; Reda J Wilson; Nicole F Dowling; Hannah K Weir; Eric W Tai; Natasha Buchanan Lunsford Journal: Cancer Date: 2020-07-29 Impact factor: 6.921